EAST – AFNET 4 has been completed!

23.07.2020

After almost a decade of successful team work we will finally have the results and will be able to answer the question whether an early and comprehensive rhythm control therapy has the potential to prevent adverse outcomes in patients with atrial fibrillation. EAST – AFNET 4 reached finally the end of study (EOS) on 3. June 2020.

The initial concept of EAST – AFNET 4 dates back more than 10 years. While antiarrhythmic drugs and catheter ablation made progress in clinical practice, the question came up whether an early and comprehensive rhythm control therapy has the potential to prevent adverse outcomes in patients with atrial fibrillation. Following this idea the EAST trial was initiated in 2009 with AFNET as sponsor.

After 2 years of preparation, patient enrolment started in summer of 2011. In the following 5 years, 2.789 patients from 135 study sites in 11 European countries were included into EAST – AFNET 4. All patients were followed-up for at least 3 years, as a long follow-up duration is essential for robust study data.

The results will be presented during one of the main hot line sessions of the 2020 Digital ESC Congress on Saturday 29 August 2020, 17.00 – 17.30 h CEST. Free registration allows online access.

The accompanying publication is in preparation. In addition to the main results paper, publications of several sub-analyses are planned. 

EAST hot line session